ArticleChinese herbal medicines2026
Multi-pathway targeting by natural products in chronic respiratory diseases: Opportunities, challenges, and future perspectives.
Article in Chinese herbal medicines, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic respiratory diseases (CRDs) are multifactorial disorders driven by dysregulated inflammation, oxidative stress, and tissue remodeling. Conventional single-target therapies are insufficient to halt disease progression, underscoring the demand for alternative therapeutic approaches. Natural products, including bioactive compounds, herbal extracts, and traditional Chinese medicine (TCM) formulas, are characterized by their inherent multi-target properties and represent a promising intervention strategy for CRDs. This perspective emphasizes natural products as network modulators that can simultaneously regulate multiple signaling pathways. The integration of systems biology, network pharmacology, and artificial intelligence (AI) is crucial for deciphering their polypharmacological mechanisms. The clinical translation of natural products is anticipated to benefit from the implementation of several key strategies, including multi-omics integration, AI, targeted delivery, and blockchain-based quality control. By shifting from a reductionist to a network-centric view, natural products can fulfill their potential as next-generation therapeutics for CRDs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.